Viveve Medical (NASDAQ: VIVE) and Derma Sciences (NASDAQ:DSCI) are both advanced medical equipment & technology – nec companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations and institutional ownership.
Valuation and Earnings
This table compares Viveve Medical and Derma Sciences’ gross revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Derma Sciences has higher revenue, but lower earnings than Viveve Medical. Derma Sciences is trading at a lower price-to-earnings ratio than Viveve Medical, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
65.6% of Viveve Medical shares are held by institutional investors. Comparatively, 58.9% of Derma Sciences shares are held by institutional investors. 35.1% of Viveve Medical shares are held by company insiders. Comparatively, 9.9% of Derma Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Viveve Medical and Derma Sciences’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a breakdown of recent ratings and recommmendations for Viveve Medical and Derma Sciences, as provided by MarketBeat.
||Strong Buy Ratings
Viveve Medical presently has a consensus price target of $10.50, indicating a potential upside of 109.58%. Given Viveve Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Viveve Medical is more favorable than Derma Sciences.
Viveve Medical beats Derma Sciences on 6 of the 10 factors compared between the two stocks.
Viveve Medical Company Profile
Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician’s office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.
Derma Sciences Company Profile
Derma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company’s advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. The Company’s traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets.
Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.